We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Keryx (KERX) Q4 Earnings: What's in Store for the Stock?
Read MoreHide Full Article
Keryx Biopharmaceuticals, Inc. is expected to report fourth-quarter 2016 results on Mar 1. Last quarter, the company recorded a negative earnings surprise of 77.27%. Let’s see how things are shaping up for this announcement.
Keryx’s share price has decreased 16.6% year to date, while the Zacks classified Medical - Biomedical and Genetics industry gained 5.9%.
Factors Influencing This Quarter
Apart from license fees, Keryx’s top line comprises revenues generated by its only marketed product, Auryxia (ferric citrate). Auryxia is approved as tablets to control serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
In August 2016, Keryx announced an interruption in the supply of Auryxia, as its contract manufacturer had issues related to the conversion of the API into the finished product, leading to a disruption in the supply of Auryxia. Consequently, the company withdrew its guidance for 2016. However, in Nov 2016, Keryx announced that the FDA has approved a second drug product manufacturer, Patheon Manufacturing Services, for supplying Auryxia as a finished product.
Following the approval, the company has rebuilt supply and expects to make Auryxia available to wholesalers. As a result of this, Aurexia sales is expected to improve in the fourth quarter of 2016.
Keryx is working on expanding ferric citrate's (the compound name for Auryxia in additional indications) label to include the treatment of iron-deficiency anemia (IDA) in patients with stage III–V non-dialysis dependent chronic kidney disease indication (NDD CKD). The company expects to file a supplemental new drug application with the FDA as soon as it receives an agreement from the FDA for its pediatric clinical plan. We expect management to update on these plans at the upcoming earnings conference call.
Surprise History
Keryx’s track record has been disappointing so far. Over the four trailing quarters, the company posted an average negative earnings surprise of 43.03%, reporting in-line earnings only once in the last four quarters, while missing the same on all the other three occasions.
What Our Model Indicates
Our proven model does not conclusively show that Keryx is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. However, that is not the case here as you will see below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00%. This is because the Most Accurate estimate and the Zacks Consensus Estimate stand at a loss of 27 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Keryx’s has a Zacks Rank #3, which increases the predictive power of ESP. However, 0.00% ESP makes surprise prediction difficult for the quarter. You can see the complete list of today’s Zacks #1 Rank stocks here.
Note that we caution against stocks with Zacks Ranks #4 or 5 (Sell-rated) going into an earnings announcement, especially when the company is seeing a negative estimate revision momentum.
Keryx Biopharmaceuticals, Inc. Price and EPS Surprise
Here are some health care stocks that you may want to consider, as our model shows that it has the right combination of elements to post an earnings beat this quarter.
Pacira Pharmaceuticals, Inc. (PCRX - Free Report) has an Earnings ESP of +20% and a Zacks Rank #2. The company is scheduled to release results on Mar 1.
Syndax Pharmaceuticals, Inc. (SNDX - Free Report) has an Earnings ESP of +18.18% and a Zacks Rank #3. The company is scheduled to release results on Mar 2.
Exelixis, Inc. (EXEL - Free Report) has an Earnings ESP of +200% and a Zacks Rank #2. The company is scheduled to release results on Feb 27.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Keryx (KERX) Q4 Earnings: What's in Store for the Stock?
Keryx Biopharmaceuticals, Inc. is expected to report fourth-quarter 2016 results on Mar 1. Last quarter, the company recorded a negative earnings surprise of 77.27%. Let’s see how things are shaping up for this announcement.
Keryx’s share price has decreased 16.6% year to date, while the Zacks classified Medical - Biomedical and Genetics industry gained 5.9%.
Factors Influencing This Quarter
Apart from license fees, Keryx’s top line comprises revenues generated by its only marketed product, Auryxia (ferric citrate). Auryxia is approved as tablets to control serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
In August 2016, Keryx announced an interruption in the supply of Auryxia, as its contract manufacturer had issues related to the conversion of the API into the finished product, leading to a disruption in the supply of Auryxia. Consequently, the company withdrew its guidance for 2016. However, in Nov 2016, Keryx announced that the FDA has approved a second drug product manufacturer, Patheon Manufacturing Services, for supplying Auryxia as a finished product.
Following the approval, the company has rebuilt supply and expects to make Auryxia available to wholesalers. As a result of this, Aurexia sales is expected to improve in the fourth quarter of 2016.
Keryx is working on expanding ferric citrate's (the compound name for Auryxia in additional indications) label to include the treatment of iron-deficiency anemia (IDA) in patients with stage III–V non-dialysis dependent chronic kidney disease indication (NDD CKD). The company expects to file a supplemental new drug application with the FDA as soon as it receives an agreement from the FDA for its pediatric clinical plan. We expect management to update on these plans at the upcoming earnings conference call.
Surprise History
Keryx’s track record has been disappointing so far. Over the four trailing quarters, the company posted an average negative earnings surprise of 43.03%, reporting in-line earnings only once in the last four quarters, while missing the same on all the other three occasions.
What Our Model Indicates
Our proven model does not conclusively show that Keryx is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. However, that is not the case here as you will see below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00%. This is because the Most Accurate estimate and the Zacks Consensus Estimate stand at a loss of 27 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Keryx’s has a Zacks Rank #3, which increases the predictive power of ESP. However, 0.00% ESP makes surprise prediction difficult for the quarter. You can see the complete list of today’s Zacks #1 Rank stocks here.
Note that we caution against stocks with Zacks Ranks #4 or 5 (Sell-rated) going into an earnings announcement, especially when the company is seeing a negative estimate revision momentum.
Keryx Biopharmaceuticals, Inc. Price and EPS Surprise
Keryx Biopharmaceuticals, Inc. Price and EPS Surprise | Keryx Biopharmaceuticals, Inc. Quote
Stocks to Consider
Here are some health care stocks that you may want to consider, as our model shows that it has the right combination of elements to post an earnings beat this quarter.
Pacira Pharmaceuticals, Inc. (PCRX - Free Report) has an Earnings ESP of +20% and a Zacks Rank #2. The company is scheduled to release results on Mar 1.
Syndax Pharmaceuticals, Inc. (SNDX - Free Report) has an Earnings ESP of +18.18% and a Zacks Rank #3. The company is scheduled to release results on Mar 2.
Exelixis, Inc. (EXEL - Free Report) has an Earnings ESP of +200% and a Zacks Rank #2. The company is scheduled to release results on Feb 27.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>